Clinical Trial Search

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…

Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants

Primary: Number of Participants With >15 ETDRS Letter Loss at Month 3 — 0 Participants

Primary: Percentage of Patients Lose Visual Acuity Less Than 15 Letters — 87.5 percentage of patients

Primary: Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA) — 14; 15; 6 Participants

Primary: BCVA — -3.50; 29.50; 8.60 number of letters read correctly

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) — 8.1; 7.9 ETDRS Letters

Primary: Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups. — 4; 24; 0; 6 Adverse events…

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye — 8.3; 5.1 Letters — p=<0.001

Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit

Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3 — 53.7; 54.2; 52.6; 63.1 ETDRS letters — p=<0.001

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters

Primary: Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage — 3; 0; 61; 121 Patients — p=<0.0001

Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters

Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 — 53.7; 54.6; 54.8; 59.0 Letters

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried…

Primary: Median Values of ERG Scotopic Parameters at 12-month — 201; 210; 508; 92 microvolts — p=<0.001

Primary: Tabulation of Adverse Events — 13 adverse events

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12 — 0.26; 0.28; 0.35 mm

Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants

Primary: Safety of Intravitreal Aflibercept Injection — 0; 0 adverse events